OBJECTIVE: To examine the risk of diabetes mellitus (DM) among subjects with rheumatoid arthritis (RA), psoriatic arthritis or psoriasis (PsA/PsO), compared with non-rheumatic controls. METHODS: Study cohorts were assembled using linked healthcare utilisation data from British Columbia. All people with at least two diagnoses of RA or PsA/PsO were included and compared with a cohort of people without any known rheumatic disease. The outcome of interest was a diagnosis of new-onset DM, as defined by initiation of an antidiabetic drug. Incidence rates (IRs) per 1000 person-years and IR ratios were calculated and Cox regression models were constructed to determine the hazard ratio (HR) for diabetes by age, gender, systemic immunosuppressive drug and glucocorticoid use. RESULTS: The study cohort comprised 48 718 subjects with RA, 40 346 with PsA/PsO and 442 033 without any rheumatic disease. The IR for DM among subjects with RA was 8.6 per 1000 person-years (95% CI 8.5 to 8.7), PsA/PsO 8.2 (95% CI 8.1 to 8.3) and for non-rheumatic controls 5.8 (95% CI 5.8 to 5.8). The adjusted HR for RA compared with non-rheumatic controls was 1.5 (95% CI 1.4 to 1.5) and 1.4 (95% CI 1.3 to 1.5) for PsA/PsO. CONCLUSIONS: RA and PsA/PsO appear to be associated with an increased risk of DM. The ability of potent antirheumatic treatments to reverse this trend warrants study.
OBJECTIVE: To examine the risk of diabetes mellitus (DM) among subjects with rheumatoid arthritis (RA), psoriatic arthritis or psoriasis (PsA/PsO), compared with non-rheumatic controls. METHODS: Study cohorts were assembled using linked healthcare utilisation data from British Columbia. All people with at least two diagnoses of RA or PsA/PsO were included and compared with a cohort of people without any known rheumatic disease. The outcome of interest was a diagnosis of new-onset DM, as defined by initiation of an antidiabetic drug. Incidence rates (IRs) per 1000 person-years and IR ratios were calculated and Cox regression models were constructed to determine the hazard ratio (HR) for diabetes by age, gender, systemic immunosuppressive drug and glucocorticoid use. RESULTS: The study cohort comprised 48 718 subjects with RA, 40 346 with PsA/PsO and 442 033 without any rheumatic disease. The IR for DM among subjects with RA was 8.6 per 1000 person-years (95% CI 8.5 to 8.7), PsA/PsO 8.2 (95% CI 8.1 to 8.3) and for non-rheumatic controls 5.8 (95% CI 5.8 to 5.8). The adjusted HR for RA compared with non-rheumatic controls was 1.5 (95% CI 1.4 to 1.5) and 1.4 (95% CI 1.3 to 1.5) for PsA/PsO. CONCLUSIONS:RA and PsA/PsO appear to be associated with an increased risk of DM. The ability of potent antirheumatic treatments to reverse this trend warrants study.
Authors: D H Solomon; N J Goodson; J N Katz; M E Weinblatt; J Avorn; S Setoguchi; C Canning; S Schneeweiss Journal: Ann Rheum Dis Date: 2006-06-22 Impact factor: 19.103
Authors: Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2006-09-25 Impact factor: 11.527
Authors: Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala Journal: J Rheumatol Date: 2006-09-01 Impact factor: 4.666
Authors: Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: JAMA Date: 2006-10-11 Impact factor: 56.272
Authors: James B Meigs; Christopher J O'donnell; Geoffrey H Tofler; Emelia J Benjamin; Caroline S Fox; Izabela Lipinska; David M Nathan; Lisa M Sullivan; Ralph B D'Agostino; Peter W F Wilson Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: Jonathan Shapiro; Arnon D Cohen; Michael David; Emilia Hodak; Gabi Chodik; Anna Viner; Eyal Kremer; Anthony Heymann Journal: J Am Acad Dermatol Date: 2006-12-08 Impact factor: 11.527
Authors: M A Gonzalez-Gay; J M De Matias; C Gonzalez-Juanatey; C Garcia-Porrua; A Sanchez-Andrade; J Martin; J Llorca Journal: Clin Exp Rheumatol Date: 2006 Jan-Feb Impact factor: 4.473
Authors: Mary Chester M Wasko; Helen B Hubert; Vijaya Bharathi Lingala; Jennifer R Elliott; Michael E Luggen; James F Fries; Michael M Ward Journal: JAMA Date: 2007-07-11 Impact factor: 56.272
Authors: Young Hee Rho; Na Lu; Christine E Peloquin; Ada Man; Yanyan Zhu; Yuqing Zhang; Hyon K Choi Journal: Ann Rheum Dis Date: 2014-10-02 Impact factor: 19.103
Authors: Yang Hu; Karen H Costenbader; Xiang Gao; May Al-Daabil; Jeffrey A Sparks; Daniel H Solomon; Frank B Hu; Elizabeth W Karlson; Bing Lu Journal: Am J Clin Nutr Date: 2014-07-16 Impact factor: 7.045